A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Karyopharm Therapeutics
Start Date
May 1, 2016
End Date
April 30, 2022
Administered By
Duke Cancer Institute
Awarded By
Karyopharm Therapeutics
Start Date
May 1, 2016
End Date
April 30, 2022